TelehealthTransparency

Home/Investigations/Mochi / Aequita

Tracked public case

Mochi Health / Aequita Pharmacy

Tracked

KING 5 “$elling $kinny” series on telehealth weight-loss drugs and Aequita Pharmacy — state inspection, Immediate Jeopardy finding, and halt of GLP-1 compounding at the supplier.

Submit a complaintPartner findings deskAll investigations

Overview

Mochi Health is a national telehealth weight-loss brand that sourced compounded GLP-1 products through Aequita Pharmacy in Kirkland, Washington. KING 5 investigative reporter Chris Ingalls and NBC Bay Area published a multi-part series (“$elling $kinny”) that followed patient complaints into the pharmacy that was actually preparing the injections.

The reporting described a gap many patients never see on a telehealth homepage: the brand that markets care is not always the entity that holds the sterile compounding license, the inspection history, or the state-board exposure. Whistleblowers and inspection records — not brand PR — drove the regulatory outcome for the pharmacy.

After state action that included an Immediate Jeopardy finding, GLP-1 compounding at Aequita was halted. The episode is now a public playbook for how telehealth packaging, pharmacy-of-record opacity, and board oversight can collide even when the telehealth brand itself is not the facility on the license.

Why we track it. Best-documented U.S. media + state-board path from patient harm narratives to a compounding-pharmacy shutdown in the GLP-1 telehealth market.

Tracked public case — media and regulatory parallel for telehealth ↔ compounding-pharmacy accountability. Comparative briefs available in the partner findings desk.

Public record timeline

  1. 2024–2025

    KING 5 / NBC “$elling $kinny” investigative series publishes patient and pharmacy findings

  2. Inspection window

    State inspection path culminates in Immediate Jeopardy finding at Aequita

  3. Aftermath

    GLP-1 compounding halted at Aequita; telehealth brand / supplier separation becomes a national case study

Focus areas

  • Whistleblower → state pharmacy board escalation path
  • Separating telehealth brand control from compounding facility accountability
  • Patient-safety, contamination, and sterile-practice narratives in public reporting
  • What happens commercially when a supplier is forced to stop compounding
  • How patients learned which pharmacy actually prepared their product

Key coverage & sources

  • KING 5 (Chris Ingalls)
  • NBC Bay Area
  • Washington state pharmacy inspection record (public)

Comparative briefs for partners live in the findings desk.